Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs Vildagliptin/Metformin in NAFLD and Type 2 Diabetes
NCT03925701Phase 3Recruiting
- Start
- Apr 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vildagliptin in non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Number of patients with improved NAFLD and insulin resistance at 6 months. Started Apr 2019; status: recruiting.
02
Drugs
vildagliptin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03925701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925701.